Selatogrel

DB15163InvestigationalSmall molecule

Selatogrel is under investigation in clinical trial NCT03814200 (A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects).

Mechanism: Pharmacologically active on P2Y purinoceptor 12
Curator reviewed
Formula / weight: C₂₈H₃₉N₆O₈P · 618.628 g/mol (avg)
Also known as: ACT-246475

Resolves to

Compound

UNII6DPK7O4PR7CAS1159500-34-1

Structure

InChIKeyFYXHWMQPCJOJCH-GMAHTHKFSA-NSMILESCCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(O)(O)=O)NC(=O)C1=CC(=NC(=N1)C1=CC=CC=C1)N1CC[C@@H](C1)OC

Targets

Q9H244P2RY12

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Selatogrel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account